We are live on ! Find out more
ANTX icon

AN2 Therapeutics
ANTX

35 hedge funds and large institutions have $10.5M invested in AN2 Therapeutics in 2025 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 11 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more capital invested

Capital invested by funds: $8.78M → $10.5M (+$1.73M)

2.83% more ownership

Funds ownership: 27.45% → 30.29% (+2.8%)

3% less funds holding

Funds holding: 36 → 35 (-1)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

36% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 11

Holders
35
Holders Change
-1
Holders Change %
-2.78%
% of All Funds
0.46%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
7
Reduced
11
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Squarepoint
Squarepoint
New York
+$62K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$50.4K
3
SCM
Stonepine Capital Management
Oregon
+$22.2K
4
AA
ACT Advisors
North Carolina
+$15.1K
5
Morgan Stanley
Morgan Stanley
New York
+$14.3K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$48K
2
LCM
Landscape Capital Management
New Jersey
-$44.5K
3
IWC
Integrated Wealth Concepts
Massachusetts
-$26.5K
4
Two Sigma Investments
Two Sigma Investments
New York
-$17.2K
5
Renaissance Technologies
Renaissance Technologies
New York
-$15.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Almitas Capital
California
$1.81M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$1.37M +$50.4K +44,123 +4%
P
3
Pfizer
New York
$908K – – –
PLC
4
Peapod Lane Capital
New York
$748K +$7.37K +6,446 +1%
SCM
5
Stonepine Capital Management
Oregon
$716K +$22.2K +19,419 +4%
Bank of Nova Scotia
6
Bank of Nova Scotia
Ontario, Canada
$583K – – –
LCM
7
Landscape Capital Management
New Jersey
$580K -$44.5K -38,933 -8%
Bank of Montreal
8
Bank of Montreal
Ontario, Canada
$536K – – –
Renaissance Technologies
9
Renaissance Technologies
New York
$490K -$15.2K -13,257 -3%
Bank of America
10
Bank of America
North Carolina
$489K -$230 -201 -0.1%
BlackRock
11
BlackRock
New York
$408K +$1.85K +1,616 +0.5%
Two Sigma Advisers
12
Two Sigma Advisers
New York
$340K -$1.94K -1,700 -0.6%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$317K – – –
Two Sigma Investments
14
Two Sigma Investments
New York
$284K -$17.2K -15,010 -6%
Morgan Stanley
15
Morgan Stanley
New York
$242K +$14.3K +12,527 +7%
State Street
16
State Street
Massachusetts
$110K – – –
RC
17
Rangeley Capital
Connecticut
$82.5K – – –
Squarepoint
18
Squarepoint
New York
$81.6K +$62K +54,205 +539%
BCM
19
Bridgeway Capital Management
Texas
$76.1K – – –
UBS Group
20
UBS Group
Switzerland
$72K -$6.07K -5,306 -9%
Northern Trust
21
Northern Trust
Illinois
$54.9K – – –
CAPTRUST Financial Advisors
22
CAPTRUST Financial Advisors
North Carolina
$50.8K – – –
Citadel Advisors
23
Citadel Advisors
Florida
$29.2K +$12K +10,516 +84%
PAG
24
Private Advisor Group
New Jersey
$28.6K – – –
XT
25
XTX Topco
Cayman Islands
$23.5K -$8.58K -7,503 -29%
1
2

ANTX Hedge Fund Activity: Q3 2025 in Review

35 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in AN2 Therapeutics (ANTX) for Q3 2025, worth a combined $10.5M — up 20% from $8.78M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of ANTX and 2 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 7 added.

The largest buyer was Squarepoint, adding an estimated $62K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $48K sold.

  • 35 institutional investors held AN2 Therapeutics (ANTX) as of Q3 2025, down from 36 in Q2 2025.
  • Funds reported $10.5M of AN2 Therapeutics stock for Q3 2025, up 20% quarter-over-quarter.
  • 2 funds opened new AN2 Therapeutics positions in Q3 2025 and 3 closed out, a net change of -1 holder.
  • The largest AN2 Therapeutics buyer in Q3 2025 was Squarepoint, an estimated $62K added.
  • The largest AN2 Therapeutics seller in Q3 2025 was Susquehanna International Group, an estimated $48K sold.

Based on aggregated 13F filings for Q3 2025.